Jeffrey Holford

Bristol-Myers Stock May Have Exhausted Its Upside For Now

Why Jefferies Upgraded Johnson & Johnson

Array BioPharma And Others Shine At The ESMO 2017 Congress

Why Jefferies Upgraded Johnson & Johnson

Array BioPharma And Others Shine At The ESMO 2017 Congress

Jefferies Strongly Reiterates Top Pick Call On AbbVie

Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Jefferies Strongly Reiterates Top Pick Call On AbbVie

Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Jefferies' 2017 Global Pharma Outlook

Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell

Jeffrey Holford Recent News

Court Date For Litigation With Amgen And Other Expectations For AbbVie

Jefferies Sees Much Larger Market Opportunity For AstraZeneca, Upgrades To Buy

Jefferies Shares Pharma Stock Catalyst Outlook

Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Amid Few Catalysts, Jefferies Downgrades AstraZeneca

Jefferies Says It's Buying Abbott Labs Stock On Emerging Market Growth, Valuation

New Report: Abbvie Is Jefferies' Top Global Pharma Stock

Could M&A Boost Pfizer More? Jefferies Thinks So

Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown

A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea

Deutsche Bank, Stifel Differ On Outlook For Eli Lilly

Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely

UPDATE: Jefferies Lowers PT on Zoetis on Challenges Ahead

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

UPDATE: Jefferies Lowers PT on Merck on Challenges Ahead

UPDATE: Jefferies Raises PT on Johnson & Johnson on Challenges Ahead

UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential